Novartis (Sweden)-ko ikertzaileekin lankidetzan egindako argitalpenak (27)

2024

  1. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer

    Lung Cancer, Vol. 197

2023

  1. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS -Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study

    Journal of Clinical Oncology, Vol. 41, Núm. 14, pp. 2651-2660

  2. Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600 Mutant Pediatric High-Grade Glioma

    Journal of Clinical Oncology, Vol. 41, Núm. 33, pp. 5174-5183

  3. Unveiling chronic spontaneous urticaria pathophysiology through systems biology

    Journal of Allergy and Clinical Immunology, Vol. 151, Núm. 4, pp. 1005-1014

2022

  1. EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)

    Future oncology (London, England), Vol. 18, Núm. 31, pp. 3481-3492

2021

  1. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study

    Arthritis and Rheumatology, Vol. 73, Núm. 2, pp. 336-346

2019

  1. Effectiveness of dabrafenib in the treatment of patients with braf v600-mutated metastatic melanoma in a named patient program

    Melanoma Research, Vol. 29, Núm. 5, pp. 527-532

2018

  1. Absence of MHC-II expression by lymph node stromal cells results in autoimmunity

    Life Science Alliance, Vol. 1, Núm. 6

  2. Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 6, Núm. 4, pp. 1191-1197.e5

2017

  1. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial

    British Journal of Haematology, Vol. 179, Núm. 1, pp. 66-74

2016

  1. IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity

    Journal of Autoimmunity, Vol. 75, pp. 39-49

  2. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

    The Lancet Haematology, Vol. 3, Núm. 11, pp. e506-e515

  3. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by prior treatment

    Blood, Vol. 127, Núm. 6, pp. 713-721

  4. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria

    Journal of Allergy and Clinical Immunology, Vol. 137, Núm. 2, pp. 474-481

2015

  1. Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma

    Haematologica

  2. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy

    Gut, Vol. 64, Núm. 2, pp. 233-242

  3. Patterns of HER2 gene amplification and response to anti-HER2 therapies

    PLoS ONE, Vol. 10, Núm. 6

  4. Pharmacometrics Markup Language (PharmML): Opening new perspectives for model exchange in drug development

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 4, Núm. 6, pp. 316-319

2014

  1. A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 3, Núm. 5

  2. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 11, pp. 1195-1206